TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04877522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib single agent
Description: Taken orally, twice daily (BID) or once daily (QD), in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib single agent
Description: Taken orally, twice daily (BID) or once daily (QD), in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib single agent
Description: Taken orally, twice daily (BID) or once daily (QD), in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Taken orally, once daily, in the morning with low-fat meal

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Taken orally, once daily, in the morning with low-fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Taken orally, twice daily, on an empty stomach

Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib
Description: Taken orally, twice daily, on an empty stomach

Intervention type: DRUG
Group type: OTHER
Intervention: Bosutinib
Description: Taken orally, once daily, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Taken orally, once daily in a fasted state, 1 or 2 hours before a meal

Intervention type: DRUG
Group type: OTHER
Intervention: Dasatinib
Description: Taken orally, once daily in a fasted state, 1 or 2 hours before a meal
Study: NCT05531773

Intervention type: OTHER
Intervention: follow up of COVID-19 Patients
Description: In each participating center a post COVID-19 outpatient clinic is already working or will be settled up to care COVID-19 patients after the acute phase. At the post COVID-19 clinic patients will undergo routine blood exams and will be visited by Infectious Diseases physicians after recovery from the acute episode of COVID-19 disease. According to the clinical issues of the patients and the procedures of the study, if necessary, the patients will be visited by other practitioners (Pneumologists, Cardiologists, Neurologists, Physiatrist and Psychologists or others).~Patients who have been already visited at the post COVID outpatient clinics from 01/03/2020 and for whom data of the acute phase and the follow up have been collected will be enrolled in the study and retrospectively analyzed.
Study: NCT06511401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PGx) results.
Description: These results are designed to provide specific dosing information based on the participant's unique genetics/genomics.
Study: NCT05402332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-801
Description: D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-801
Description: D-Galactose medical grade supplement - 1.5g/kg/day (not to exceed 50 g/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo equivalent
Study: NCT06527638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: eHealth intervention for UI symptoms improvement
Description: The intervention was theoretically based on the HAPA model (including effective strategies in behaviour change, for example, action planning and coping with obstacles) and Common Sense Model of Self Regulation (beliefs, coping and appraisal), focusing on risk perception, planning, and self-efficacy.~The intervention consisted of 8 sessions (90 minutes, once a week). All group intervention sessions, through the Zoom platform, were led by the psychologist responsible for the study, except the second session that was led by a physiotherapist. WhatsApp groups were created, to share experiences, knowledge, doubts and fears, and to create a sense of belonging, understanding and cohesion.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Delivery of a Health Literacy single-leaflet
Description: A health literacy single-leaflet was delivered, by e-mail in the first week of the intervention. Beyond this, there was no further interaction with the group.~All primary and secondary outcome measures were assessed at baseline, mid-intervention (one month later), post-intervention, and in a 3 month follow-up after the intervention.
Study: NCT06191198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Bridge™
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Impairment Focused
Description: Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
Study: NCT06645327

Intervention type: OTHER
Intervention: a change in operating room table position, which will mimic an IV fluid bolus
Description: Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained

Intervention type: OTHER
Intervention: a change in operating room table position, which will mimic an IV fluid bolus
Description: Cardiac Output (CO) measurements will be obtained at two separate time points: prior to sternotomy (opening of the chest) and after separation from cardiopulmonary bypass.~Intervention~1. the participant will be placed in the reverse Trendelenburg position (head up) to 15 degrees for 60-90 seconds. CO measurement will be obtained~2. the participant will be transitioned to the Trendelenburg position (head down) to 15 degrees for 60-90 seconds. CO measurement will be obtained
Study: NCT05709106

Intervention type: DRUG
Intervention: Rimegepant 75 MG
Description: Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year
Study: NCT06643351

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intrapartum Glucose Target Range
Description: Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-110mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 110 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liberalized Intrapartum Glucose Target Range
Description: Intrapartum maternal glucose management involves frequent blood sugar checks and the use of insulin intravenous drip as needed. Maternal capillary blood sugar is checked every 4 hours in early labor, 2 hours in active labor and hourly during the second stage of labor. The frequency of maternal glucose monitoring will not differ by study group. The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL. Once an insulin infusion is initiated, glucose monitoring frequency will occur by protocol. A hypoglycemia protocol is initiated if the maternal blood sugar is less than 60mg/dl.
Study: NCT06575140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Associative Peripheral Stimulation (APS) 1.0
Description: Associative peripheral stimulation paired with rehabilitative exercises.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Neuromuscular Stimulation
Description: Random peripheral stimulation paired with rehabilitative exercises.
Study: NCT05392062

Intervention type: OTHER
Group type: OTHER
Intervention: Pathophysiology of gas exchange
Description: Exploration of pathophysiology of gas exchange
Study: NCT04729322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo colonoscopic FMT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo colonoscopic FMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation Capsule
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Given PO
Study: NCT05552014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Natural Psychotherapy
Description: Natural psychotherapy is based on Morita therapy and is a psychotherapy that fully reflects the characteristics of Chinese culture, taking into account the Chinese cultural background and actual clinical characteristics.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mental Health Education
Description: Mental Health Education Seminar
Study: NCT05395091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT03
Description: AVT03 (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL to be administered as a subcutaneous injection. Subjects in this arm will receive AVT03 60mg administered s.c. At Month 12, subjects in the AVT03 arm will receive a third dose of AVT03 60 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Prolia (denosumab) is a recombinant fully human IgG2 monoclonal antibody to RANKL developed to be administered as a subcutaneous injection.~Subjects will receive 60mg of commercially available US-Prolia, administered s.c At Month 12, subjects in the Prolia treatment group will be re-randomized in a 1:1 ratio to receive either:~* Group 2a: Subjects will receive AVT03 60 mg administered s.c. on Day365.~* Group 2b: Subjects will receive Prolia 60 mg administered s.c. on Day365.
Study: NCT05145309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KMgCit
Description: Supplement that provide K, Mg, and citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KMgCit
Description: Supplement that provide K, Mg, and citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Power with identical appearance to KMgCit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Power with identical appearance to KMgCit
Study: NCT06462508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-PSMA-N5
Description: Each subject receive a single intravenous injection of \[18F\]F-PSMA-N5, and undergo PET/CT imaging within the specificed time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: Each subject receive a single intravenous injection of \[68Ga\]Ga-PSMA-11, and undergo PET/CT imaging within the specificed time.
Study: NCT02645734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 1.25 mg of bevacizumab is injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziv-aflibercept 1.25 mg
Description: 1.25 mg of ziv-aflibercept is injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziv-aflibercept 2.5mg
Description: 2.5 mg of ziv-aflibercept is injected
Study: NCT06579118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: The women in the experimental group were given laughter yoga sessions by the researcher.
Study: NCT06508281

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: . Anatomy model videos prepared by the researchers for the experimental group students will be uploaded to Google Drive and sent via link. Students will be asked to log in from their computer or mobile phone and watch anatomy model videos whenever and wherever they want
Study: NCT05040009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: integrated foot care program
Description: 1. Regular foot care and examination by an adequately trained professional: -~2. Structured education:~Educational modality will be provided to patients in a structured way. This will take many forms: one-to-one verbal education session last around 30 min motivational interviewing, video education, booklets, pictorial education via animated drawing or descriptive images structured foot care education consists of information on:~1. Foot ulcers and their consequences~2. Preventative foot self-care behaviors~3. Wearing adequately protective footwear~4. Undergoing regular foot checks~5. Practicing proper foot hygiene~6. Seeking professional help in a timely manner after identifying a foot problem~3-Adequate footwear 4-Foot-related exercises and weight-bearing activity 5-Foot examination and screening 6- Instructions about foot self-management
Study: NCT06333808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match B/F/TAF
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match BIC/LEN
Description: Tablets administered orally without regard to food
Study: NCT05770999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender application
Description: Lavender application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender application
Description: Lavender application
Study: NCT05918705

Intervention type: PROCEDURE
Intervention: Ultrasound optic nerve sheath diameter / eyeball transverse diameter ratio
Description: Ocular ultrasonography will be performed once daily on patients diagnosed with sepsis associated encephalopathy at the bedside by two experienced examiners, who will be blinded to patients' clinical data, following the CLOSED protocol for ONSD sonography.~ONSD will be measured at 3 mm behind the merging point of the nerve from the papilla optic disc. The maximum external diameter of ONSD will be measured in the transverse plane perpendicular to the optic nerve and the maximum diameter of ETD (parallel lens) on this plane will be measured.~Two measurements will be taken for each eye; horizontal and vertical. The sequence for measurements will be left eye horizontal; left eye vertical; right eye horizontal; right eye vertical.~The ONSD measurements in the transversal and the sagittal plane for each eye measured by the two examiners will be averaged. Then, ETDs measurements will be averaged to obtain averaged ONSD/ETD ratio as a data to record the mean values of ONSD/ETD ratio.
Study: NCT06144086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscenvivint
Description: Administered by intravenous (IV) infusion over 3-4 hours
Study: NCT04978506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05630547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet by oral administration
Study: NCT05694741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0186
Description: Subjects will receive AZD0186 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0186
Description: Subjects will receive AZD0186 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0186
Description: Subjects will receive AZD0186 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0186
Description: Subjects will receive AZD0186 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive placebo orally.
Study: NCT06648642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS applies a strong (\~2 Tesla), rapidly changing electro-magnetic field at the scalp to induce electrical current flow in underlying brain tissues
Study: NCT04331704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP acronym (pre-exposure prophylaxis)
Description: A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP acronym (pre-exposure prophylaxis)
Description: A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Initial Web Survey
Description: Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Web Survey
Description: Web-based assessment questions regarding alcohol and other substance use and sexual health behaviors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Response (IVR) monitoring
Description: Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational material on alcohol and sexual health behavior
Description: Educational material to provide information, resources and techniques to enhance awareness regarding alcohol and other substance use, along with sexual health behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) assessment with personalized information
Description: Daily telephone-based assessment on alcohol and other substance use, sexual health behavior and PrEP taking with personalized and information based on daily IVR responses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized information based on web-based survey responses & standardized information
Description: Personalized and information on alcohol use and sexual health behavior based on responses to the web-based survey along with standardized information.
Study: NCT05026112

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: ECG imaging acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: ECG imaging acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: ECG imaging acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG-Imaging
Description: ECG imaging acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI scan
Description: Cardiac MRI scan
Study: NCT06106412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ionomycin SIGMA
Description: Oocytes will be activated with Ionomycin SIGMA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A23187
Description: Oocytes will be activated with A23187
Study: NCT04836273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Abdominal s.c. self-administration 120 µg of dasiglucagon when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Study: NCT05612347

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: Annual FIT